Drugs Containing Excipient (Inactive Ingredient) DOCUSATE SODIUM

Branded drugs containing DOCUSATE SODIUM excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	PROPECIA	finasteride	0006-0071	DOCUSATE SODIUM
Merck Sharp & Dohme Corp	PROSCAR	finasteride	0006-0072	DOCUSATE SODIUM
Pharmacia & Upjohn Company LLC	HALCION	triazolam	0009-0017	DOCUSATE SODIUM
PHARMACIA & UPJOHN COMPANY LLC	XANAX	alprazolam	0009-0029	DOCUSATE SODIUM
AbbVie Inc	TRICOR	fenofibrate	0074-3173	DOCUSATE SODIUM

Generic drugs containing DOCUSATE SODIUM excipient

Company	Ingredient	NDC	Excipient
Merck Sharp & Dohme Corp	finasteride	0006-0071	DOCUSATE SODIUM
Merck Sharp & Dohme Corp	finasteride	0006-0072	DOCUSATE SODIUM
Pharmacia & Upjohn Company LLC	triazolam	0009-0017	DOCUSATE SODIUM
PHARMACIA & UPJOHN COMPANY LLC	alprazolam	0009-0029	DOCUSATE SODIUM
AbbVie Inc	fenofibrate	0074-3173	DOCUSATE SODIUM

Docusate Sodium Market Dynamics, Financial Trajectory, Patents, and Supply Chain

Last updated: August 23, 2026

Docusate sodium is a mature, low-margin pharmaceutical ingredient with two commercial roles: an active ingredient in stool-softener products and an excipient used as a surfactant, wetting agent, or solubilizer. Its market is volume-driven rather than innovation-driven. The active ingredient has no meaningful current compound-patent barrier, FDA exclusivity is limited to product-specific regulatory rights, and biosimilar risk is irrelevant.

Demand is stable in institutional and over-the-counter channels but faces substitution from polyethylene glycol, senna combinations, fiber products, and newer bowel-management protocols. Financial performance depends on manufacturing scale, regulatory compliance, supply reliability, and access to high-volume generic and private-label customers. Public companies do not generally disclose docusate sodium revenue separately.

What is docusate sodium and how is it used in pharmaceuticals?

Docusate sodium, CAS Registry Number 577-11-7, is the sodium salt of dioctyl sodium sulfosuccinate. It is an anionic surfactant with stool-softening activity. In pharmaceutical manufacturing, it can also improve wetting and dispersion in oral solid and liquid formulations.

Attribute	Description
Chemical name	Dioctyl sodium sulfosuccinate
Common abbreviations	DSS, docusate sodium
Primary dosage forms	Capsules, softgels, tablets, liquids, oral solutions
Primary therapeutic use	Stool softener
Excipient functions	Wetting agent, surfactant, solubilizer, dispersion aid
Regulatory status	Established pharmaceutical ingredient; U.S. OTC laxative use is governed by FDA requirements
Biosimilar relevance	None
Patent profile	Mature compound with no meaningful current foundational patent barrier
Main commercial channels	OTC products, generic medicines, hospital supply, compounding, excipient distribution

Docusate sodium is listed in the FDA Inactive Ingredient Database for certain pharmaceutical uses. The database is route-, dosage-form-, and maximum-potency-specific, so formulation developers must evaluate the current entry for the intended product rather than rely on the ingredient’s historical use alone.[1]

How large is the docusate sodium market?

No audited public market size exists for docusate sodium as a standalone excipient or active ingredient. Commercial market reports often combine docusate sodium with docusate calcium, stool-softener products, laxatives, or broader pharmaceutical excipients. Those categories are not interchangeable and produce materially different revenue estimates.

The addressable market has three layers:

1. Docusate sodium as an active pharmaceutical ingredient in branded and generic stool softeners.
2. Docusate sodium sold as an excipient to pharmaceutical manufacturers and compounders.
3. Finished consumer products containing docusate sodium.

The finished-product market is materially larger than the bulk excipient market because formulation, packaging, retail distribution, and brand margins are included. Bulk docusate sodium pricing is constrained by the availability of multiple chemical manufacturers and the absence of product differentiation in routine applications.

What determines docusate sodium pricing?

Pricing is driven by:

• Pharmaceutical grade and compendial compliance.
• Manufacturing location and regulatory history.
• Batch size and annual-volume commitments.
• Documentation requirements, including certificates of analysis and elemental-impurity controls.
• Packaging, moisture protection, and particle-size specifications.
• Customer qualification status.
• Freight, tariffs, and currency movements.
• Supply interruptions at Asian manufacturing sites.

The material is generally a low-cost, high-volume ingredient. Contract pricing is usually more important than spot pricing. Pharmaceutical customers may pay a premium for qualified supply, audit history, change-control discipline, and dual-source support.

What is the financial trajectory for docusate sodium?

The financial trajectory is mature to mildly declining in developed markets, with intermittent volume growth in emerging markets and institutional channels.

Financial driver	Direction	Commercial effect
U.S. OTC stool-softener demand	Flat to declining	Limits branded volume growth
Hospital and post-operative use	Mixed	Supports baseline demand but faces protocol substitution
Excipient applications	Stable but small	Provides diversification without strong pricing power
Generic competition	High	Keeps selling prices low
Manufacturing consolidation	Periodic	Can create short-term price increases during shortages
Raw-material and freight costs	Volatile	Compresses margins when contracts lag cost inflation
Regulatory documentation	Rising	Favors qualified suppliers and increases compliance cost
Product innovation	Limited	Reduces opportunities for premium pricing

Finished-product economics differ from bulk-ingredient economics. A branded stool-softener manufacturer can preserve margins through packaging, retail placement, combination products, and channel management even when the active ingredient represents a small portion of total cost. Bulk suppliers do not receive the same margin benefit.

Kenvue, Perrigo, generic-drug companies, contract manufacturers, and private-label marketers report broader consumer-health or pharmaceutical segments rather than docusate-specific sales. Public filings therefore cannot be used to derive a reliable company-level docusate sodium revenue ranking.[2][3]

Which companies supply or commercialize docusate sodium?

The commercial landscape is fragmented.

Bulk ingredient suppliers

Bulk supply includes manufacturers and distributors in India, China, Europe, and North America. Supplier qualification typically focuses on:

• Current good manufacturing practice compliance.
• USP-NF or equivalent compendial testing.
• Identity, assay, related substances, water, residue on ignition, and elemental impurities.
• Change-notification procedures.
• DMF or equivalent regulatory support where applicable.
• Audit access and supply-continuity planning.

Distributors and laboratory suppliers commonly sell smaller quantities to compounders, development laboratories, and research customers. These channels carry higher per-kilogram prices but do not represent the principal commercial volume.

Finished-product companies

Docusate sodium is present in branded, generic, hospital, and private-label stool-softener products. Examples of commercial product categories include:

• Docusate sodium capsules and softgels.
• Oral solutions and liquids.
• Combination laxative products.
• Hospital formulary products.
• Pharmacy-compounded preparations.

Brand ownership can change through acquisitions, divestitures, licensing, or private-label arrangements. The presence of docusate sodium in a finished product does not establish that the marketer manufactures the API.

What FDA regulatory status applies to docusate sodium?

In the United States, docusate sodium is used in OTC laxative products under the FDA’s nonprescription-drug framework. The relevant regulatory analysis depends on whether the product is marketed under an OTC monograph, approved through an NDA, or submitted through an ANDA.

The FDA regulates the finished dosage form, not merely the purchase of bulk docusate sodium. A manufacturer must establish that the ingredient is suitable for the intended use, meets applicable specifications, and is manufactured under appropriate quality systems.

Key regulatory issues include:

• Whether the finished product complies with the applicable OTC monograph conditions.
• Whether the selected dosage form and strength are permitted.
• Whether inactive-ingredient use is supported for the route and formulation.
• Whether the supplier has adequate qualification and change-control records.
• Whether the product has stability, dissolution, assay, and impurity data.
• Whether labeling and claims comply with FDA requirements.

FDA’s OTC laxative regulation identifies permitted active ingredients and conditions of use for orally administered laxative products.[4] The FDA’s Inactive Ingredient Database is relevant when docusate sodium is used for a function other than the active stool-softener role.[1]

What is the Orange Book status of docusate sodium?

The Orange Book is not a complete market register for every docusate sodium product. It primarily covers approved prescription and certain approved drug products, along with therapeutic-equivalence information and listed patents or exclusivity where applicable.[5]

Docusate sodium products marketed under the OTC monograph framework generally do not create the same Orange Book patent profile as a newly approved prescription drug. As a result:

• There is no single Orange Book entry that captures the entire docusate sodium market.
• OTC monograph products generally do not rely on a branded NDA patent estate.
• Patent listings must be reviewed product by product.
• A lack of an Orange Book listing does not eliminate non-Orange-Book litigation risk.
• Private-label and generic products may have limited public patent information.

What patents protect docusate sodium?

No commercially significant active U.S. compound patent protects docusate sodium itself. The molecule and its core therapeutic use are long-established. Any foundational composition or basic-use patents would have expired decades ago.

Current intellectual-property protection, where it exists, is more likely to concern:

• A particular liquid or softgel formulation.
• Taste masking or flavor systems.
• Controlled-release delivery.
• Combination products containing docusate and another laxative.
• Packaging or dosing systems.
• Manufacturing processes and impurity-control methods.
• Specific methods of treating constipation in a defined patient population.

These rights are narrower than a compound patent and may not apply to ordinary docusate sodium capsules or bulk excipient sales.

What are the patent expiration dates?

There is no commercially relevant single expiration date for docusate sodium because the core molecule is off-patent. Patent expiration must be assessed separately for any formulation, combination, process, or method-of-use patent asserted against a specific product.

For U.S. patents, the standard term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and transitional rules.[6] A formulation patent filed recently would therefore have a substantially later expiration date than the underlying docusate sodium compound, but the patent would protect only the claimed formulation or method.

Are there Paragraph IV challenges involving docusate sodium?

Paragraph IV litigation risk is limited because docusate sodium is a mature ingredient and many products are not dependent on a branded NDA patent estate.

A Paragraph IV certification is relevant when an ANDA applicant seeks approval for a product that references an NDA and challenges a listed patent. The practical risk depends on:

• Whether a reference NDA exists.
• Whether patents are listed in the Orange Book.
• Whether the challenged claims cover the proposed formulation or use.
• Whether the reference product qualifies for 30-month-stay litigation consequences.
• Whether the product is instead marketed under an OTC monograph pathway.

For ordinary docusate sodium products, the main competitive threat is usually regulatory and commercial substitution rather than patent litigation. Litigation may still arise over a specific softgel, liquid formulation, combination product, or branded delivery system.

What formulations are protected by docusate sodium patents?

The most defensible formulation claims would typically require a defined composition or performance characteristic. Potential claim areas include:

Softgels and capsules

Softgel formulations may raise issues involving shell composition, fill viscosity, dissolution, leakage control, and stability. These features can be difficult to design around if a patent claims a narrow combination of excipients and processing conditions, but ordinary docusate sodium capsules remain readily substitutable.

Oral liquids

Liquid products may require flavor masking, suspension stability, preservative systems, pH control, and dose uniformity. Formulation patents are more plausible in this category than for standard hard capsules.

Combination laxatives

Products combining docusate sodium with stimulant laxatives or other bowel-regimen ingredients may carry method-of-use, dosing, or formulation claims. The strength of such patents depends on claim scope and clinical or formulation evidence.

Excipient applications

Use as a wetting agent or surfactant is generally a formulation-selection decision. Patent risk may attach to a finished dosage form rather than to the purchase or use of docusate sodium as a commodity ingredient.

How strong is the docusate sodium patent estate?

The patent estate is weak at the molecule level and potentially moderate only for narrow product-specific formulations.

Patent layer	Current risk
Core compound	Very low
Basic stool-softener use	Very low
Standard capsule formulation	Low
Softgel or liquid formulation	Product-specific
Combination laxative	Product-specific
Manufacturing process	Moderate if process is difficult to replicate
Trade secrets and know-how	More relevant than patents
Excipient use	Usually low, unless embedded in a patented dosage form

Manufacturing know-how can create a practical barrier even without enforceable patent protection. Important know-how may include control of sulfosuccinate ester composition, residual impurities, color, odor, particle characteristics, and batch-to-batch consistency.

What generic launch scenarios exist for docusate sodium?

The most likely generic and private-label launch scenarios are:

1. Direct substitution through an OTC monograph-compliant product.
2. ANDA-based entry where an approved reference product and applicable patent listing exist.
3. Private-label launch using a qualified API and contract manufacturer.
4. Hospital-formulary entry after product qualification and purchasing approval.
5. Combination-product entry using docusate sodium with another laxative.

Launch barriers are usually low for standard solid oral products. They rise for liquids, softgels, pediatric products, and products requiring specialized stability or taste-masking data.

What competitive products substitute for docusate sodium?

Docusate sodium competes with products that address constipation through different mechanisms.

Product class	Competitive position
Polyethylene glycol	Strong substitute in many chronic-use settings
Senna and stimulant laxatives	Strong substitute for short-term bowel relief
Psyllium and fiber	Preferred for some long-term regimens
Lactulose	Used when osmotic therapy is clinically preferred
Magnesium-based laxatives	Compete in episodic constipation
Docusate calcium	Direct chemical alternative with limited differentiation
Enemas and suppositories	Compete where rapid local action is needed

Clinical evidence has questioned the effectiveness of docusate in some hospital and critically ill populations. A randomized trial in hospice patients found no meaningful benefit from docusate plus senna compared with senna alone, while broader evidence reviews have not established a strong advantage over other laxatives.[7][8] These findings can affect institutional protocols and long-term volume growth even when the product remains available and inexpensive.

What manufacturing and geographic risks affect docusate sodium?

The supply chain is geographically diversified but concentrated in Asian chemical manufacturing for cost-sensitive bulk production. Risks include:

• Dependence on a limited number of qualified producers.
• Export restrictions or customs delays.
• Plant shutdowns and environmental inspections.
• Changes in raw-material availability.
• Variations in ester composition and impurity profile.
• Inadequate supplier change notification.
• Freight-cost volatility.
• Failure to maintain compendial or GMP status.

A pharmaceutical customer should treat supplier qualification as a commercial asset. Switching suppliers can require comparative testing, stability work, regulatory notifications, and customer approval even when the chemical name remains unchanged.

Europe, the United States, India, and China have the most relevant commercial roles across manufacturing, distribution, formulation, and finished-product sales. Geographic protection is generally regulatory rather than patent-based. A supplier with approved documentation in one jurisdiction may still require separate qualification for another market.

What licensing deals and settlement agreements affect docusate sodium?

No major current licensing platform or market-defining patent settlement is associated with docusate sodium as a commodity ingredient. Commercial arrangements are more likely to be private supply contracts, contract manufacturing agreements, private-label arrangements, and distribution agreements.

Settlement agreements may arise in disputes involving a branded combination product or formulation, but they do not define the economics of the underlying docusate sodium market. Any settlement assessment must focus on the specific NDA, patent claims, product formulation, and launch restrictions rather than on docusate sodium generally.

Key Takeaways

• Docusate sodium is a mature, off-patent pharmaceutical ingredient and OTC active.
• Its bulk excipient market is smaller and less transparent than the finished stool-softener market.
• Public companies generally do not report docusate sodium revenue separately.
• Pricing is determined by volume, supplier qualification, GMP status, documentation, and supply reliability.
• The molecule has no meaningful current foundational patent barrier.
• Formulation, combination-product, process, and method-of-use patents can create narrow product-specific risks.
• Paragraph IV exposure is limited for ordinary OTC products but can arise for NDA-linked formulations.
• Biosimilar competition does not apply.
• Polyethylene glycol, senna, fiber, and other laxative classes constrain long-term growth.
• Manufacturing know-how and regulatory qualification are more commercially important than patents.

FAQs

Is docusate sodium an excipient or an active pharmaceutical ingredient?

It can be either. In stool-softener products, docusate sodium is the active ingredient. In other oral formulations, it can function as a surfactant, wetting agent, or solubilizer.

Is docusate sodium approved for pediatric formulations?

Pediatric use depends on the specific product, strength, dosage form, labeling, and jurisdiction. A supplier’s general pharmaceutical-grade status does not establish pediatric approval.

Can docusate sodium be used in injectable products?

Use in an injectable product requires route-specific regulatory and safety support. Oral use or oral excipient precedent does not automatically support parenteral administration.

Does docusate sodium have a Drug Master File?

A manufacturer may maintain a DMF or equivalent confidential regulatory file, but DMF existence and reference status are supplier-specific. A DMF is not a patent and does not create market exclusivity.

What is the main investment risk in the docusate sodium market?

The principal risk is volume erosion from clinical substitution and low-cost competition, not loss of patent exclusivity. Supplier disruption can produce short-term pricing opportunities, but durable margin expansion is difficult without differentiated formulation, regulatory qualification, or contract access.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. Kenvue Inc. (2024). 2023 annual report. https://investors.kenvue.com
3. Perrigo Company plc. (2024). 2023 annual report. https://investor.perrigo.com
4. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 334: Laxative drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-334
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
6. United States Patent and Trademark Office. (2024). Patent term adjustment and patent term. https://www.uspto.gov/patents/laws/patent-term-adjustment
7. Tarumi, Y., et al. (2013). Randomized, double-blind, placebo-controlled trial of oral docusate in hospice patients. Journal of Pain and Symptom Management, 45(1), 2-9.
8. Young, J. B., et al. (2013). Docusate in critically ill patients: A randomized controlled trial. Journal of Critical Care, 28(4), 515-519.